By REUTERS
Stocks in the Swiss drugmaker fell more than 5 percent after the announcement that trials of Kadcyla, for breast cancer, and gantenerumab, for Alzheimer’s disease, were ending.
Published: December 20, 2014 at 12:00AM
from NYT Business Day http://ift.tt/13lqCkA
from WordPress http://ift.tt/1DSvZso
via Hadi Aboukhater
No comments:
Post a Comment